Drug Profile
BI 1181181
Alternative Names: BI-1181181; VTP-37948Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Vitae Pharmaceuticals
- Developer Boehringer Ingelheim
- Class Nootropics; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 07 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in Belgium (PO)
- 01 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In the elderly, In volunteers, In adults) in Germany (PO)